Lebrikizumab, Placebo for Lebrikizumab, MOMETASONE
J2T-MC-KGBT
Phase 3 small_molecule active
Quick answer
Lebrikizumab, Placebo for Lebrikizumab, MOMETASONE for Perennial Allergic Rhinitis (PAR) is a Phase 3 program (small_molecule) at Eli Lilly Co. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Eli Lilly Co.
- Indication
- Perennial Allergic Rhinitis (PAR)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active